DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Alimera Sciences
Alimera Sciences
NASDAQ Stock Market
Advances in Management of Diabetic Retinopathy Featuring the P
Medicaid System (Mmis) Illinois Department of Run Date: 08/08/2015 Provider Subsystem Healthcare and Family Services Run Time: 21:25:58 Report Id 2794D052 Page: 01
05/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 04:25:50 Report Id 2794D052 Page: 01
Rebateable Manufacturers
Psivida and Pfizer Amend Agreement to Focus Solely on Development Of
The Bottom 99
MANUFACTURERS with CMS AGREEMENTS AS of 5-14-21 Labeler Code Labeler Name Program End Date 00002 ELI LILLY and COMPANY 00003 E.R
Table of Contents
Supplier Name
Psivida Generates up to A$82M from Licensing Amendment with Alimera
Fueling Life Sciences Through Transformative Transactions
SSSB Minutes 2020 06 FINAL
13 Annual Medical Director/ Physician Leadership Forum Expo May 15
Psivida Reports Receipt by Alimera Sciences of Complete Response Letter from FDA for ILUVIEN(R) for DME
FULL NAME Contact Company ID Email 3M Company Suzanne Danielson CC0013
[email protected]
3M Unitek Corporation Vincent Martinez CC0361
[email protected]
A-Dec, Inc
Psivida Receives $15 Million Payment from Alimera Sciences
Show Me Past Attendees to This Event
Top View
02/10/2015 Provider Subsystem Healthcare and Family Services Run Time: 20:51:09 Report Id 2794D051 Page: 01
Medicaid System (Mmis) Illinois Department of Run Date: 02/10/2015 Provider Subsystem Healthcare and Family Services Run Time: 20:51:09 Report Id 2794D052 Page: 01
Alimera Sciences Inc
Presenter Financial Disclosures for AAO 2020
Retina Update: the 10Th Annual J
Psivida Announces Phase I/II Clinical Study Evaluating Bioerodible, Sustained Release Latanoprost Device in Ocular Hypertension and Glaucoma
Active Labelers Run Date : Aug 26, 2021
A Comparison of the Efficacy of Brolucizumab and Aflibercept in Eyes with Early Persistent Retinal Fluid: 96–Week Results from the HAWK and HARRIER Studies
Taking the Right Measures to Control COVID-19 in Ophthalmology: the Experience of a Tertiary Eye Care Referral Center in Italy
THREE PILLARS of SUCCESS in Patient and Practice Management Strategies in Diabetic Macular Edema
4Q2015 Active Labeler Labeler Company 00002 ELI LILLY and COMPANY 00003 E.R
Customer Rebate List Covering
2020 Membership Benefits Guide
Alimera Sciences. Page 2 of 20
[email protected]
The Pharma 1000 Top Global Pharmaceutical Company Report
List of Section 13F Securities, Fourth Quarter 2019
Alimera Sciences Inc
Draft Scope (Post-Referral)